Allogene Therapeutics Announces Participation in the Jefferies Cell and Genetic Medicine Summit

Posted: September 25, 2022 at 2:04 am

SOUTH SAN FRANCISCO, Calif., Sept. 23, 2022 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced that management plans to present at the Jefferies Cell and Genetic Medicine Summit on Friday, September 30, 2022 at 6:30AM Pacific Time/9:30AM Eastern Time.

Read the rest here:
Allogene Therapeutics Announces Participation in the Jefferies Cell and Genetic Medicine Summit

Related Posts